Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …

Introduction Camrelizumab, a humanized immunoglobulin G4-κ monoclonal antibody
against programmed cell death protein 1, has exhibited antitumor activity and tolerability …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …

Immunotherapy has become an established pillar of cancer treatment improving the
prognosis of many patients with a broad variety of hematological and solid malignancies …

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …